Psilocybin treatment study for opioid use disorder
Treatments studied
Part of Mental health clinical trials.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old and physically healthy.
- You are staying at a residential addiction treatment center and plan to remain there during the study.
- You are already taking a stable dose of buprenorphine/naloxone (Suboxone), methadone, or have had a Sublocade injection in the past month.
- You do not have a history of serious mental health conditions like schizophrenia, bipolar disorder, or recent suicidal thoughts.
- You have no major heart problems, uncontrolled high blood pressure, or a history of seizures.
- You can read and understand English and have no metal implants that could interfere with an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
This study tests whether psilocybin (a compound found in certain mushrooms), given with therapy, can help people with moderate to severe opioid use disorder reduce their opioid use. Participants must have stable housing and a support person to join.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.